Trimebutine: Mechanism of Action, Effects on Gastrointestinal Function and Clinical Results

Delvaux, M; Wingate, David

doi:10.1177/030006059702500501

Cited by 84 publications

(72 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The action of trimebutine in the gastrointestinal tract is mediated via an agonist effect on opiate receptors, the release of gastrointestinal peptides such as motilin, and modulation of the release of other peptides, including vasoactive intestinal peptide, gastrin, and glucagons (Delvaux and Wingate, 1997). As regards the mechanism of trimebutine's effect, several investigations indicated a direct action of trimebutine on the contraction of the isolated smooth muscles of the small intestine and colon.…”

Section: Discussionmentioning

confidence: 99%

“…The action of trimebutine in the gastrointestinal tract may be due to various pharmacological mechanisms mediated via an agonist effect on peripheral mu, kappa and delta opiate receptors, the release of gastrointestinal peptides such as motilin, and modulation of the release of other peptides, including vasoactive intestinal peptide, gastrin, and glucagons (Tanaka, 1998;Uchiyama et al, 2000;Kountouras et al, 2002). In clinical practice, trimebutine has been used in the treatment of patients with disturbances of gastrointestinal motility, such as abdominal pain, dyspepsia and irritable bowel syndrome (Delvaux et al, 1997).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Synergic Effect of Trimebutine Combined with Mosapride on Gastrointestinal Dysfunction and Visceral Pain Induced in Stress Models

Park¹,

Park²,

Chung³

et al. 2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

Abstractgastric neurosis, gastroptosis, or refl ux esophagitis (Wingate et al., 2002). Even though there have been great advances in our understanding of the neurohumoral mechanisms controlling gastrointestinal motility in health and disease, the underlying pathogenesis of this condition is not fully understood, therefore, various drugs are used in the treatment of gastrointestinal motility disorders.A gastroprokinetic agent is a type of drug which enhances gastrointestinal motility by increasing the frequency of con-

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Synergic Effect of Trimebutine Combined with Mosapride on Gastrointestinal Dysfunction and Visceral Pain Induced in Stress Models

Park¹,

Park²,

Chung³

et al. 2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

show abstract

“…It is stimulatory in case of hypomotility states and inhibitory in case of hypermotility states. 3 Although the success rate is approximately 50% in adults, it is important to note that it was more than 90% in children population in terms of pain and abdominal discomfort. It suggests that opioid receptors have an important role in the pathogenesis of childhood IBS.…”

Section: To the Editormentioning

confidence: 99%

Importance of Rectal Urgency in Childhood Irritable Bowel Syndrome

Topaloğlu

Akbal

Yıldırım

2014

J Neurogastroenterol Motil

View full text Add to dashboard Cite

TO THE EDITOR:We read with interest the article titled "The incidence of irritable bowel syndrome in children using the Rome III criteria and the effect of trimebutine treatment" by Karabulut et al 1 that is a rare and a valuable study from our country.As the author stated, functional dyspepsia and urgency are very common symptoms in irritable bowel syndrome (IBS) patients. Although the association with the functional dyspepsia is known there is limited study regarding the frequency of rectal urgency in literature and we consider this knowledge to be of importance. In adult studies it was reported that rectal urgency is common especially in diarrheal type of IBS, although it is not included in the Rome III criteria. Cheng et al 2 in their study indicated 83% association between rectal urgency and IBS in only 6 cases. Karabulut et al 1 reported frequency of rectal urgency as 66.7% in children.That shows rectal urgency is an important symptom in childhood IBS and shed light on new studies about its utility as a diagnostic criteria. It was also shown that colonic motility is related with opioid receptors in colon by pathophysiologic studies. Another important point from the study is the successful result with the trimebutine maleate that is effective on opioid receptors. Current treatments are not effective enough against IBS symptoms and new treatment modalities are necessary. Trimebutin maleate, one of the treatment options, shows encephalin like effect and binds to intestine smooth muscle μ and δ receptors. It is stimulatory in case of hypomotility states and inhibitory in case of hypermotility states.3 Although the success rate is approximately 50% in adults, it is important to note that it was more than 90% in children population in terms of pain and abdominal discomfort. It suggests that opioid receptors have an important role in the pathogenesis of childhood IBS. In a recent study, it was shown that urgency symptoms improved markedly with Eluxadoline that exerts its effects by opioid receptors. 4 However, recovery of the IBS symptoms was evaluated according to the last week's pain and abdominal discomfort. Therefore, it is yet a question weather the drug has a long-term effect or not. Last but not least, IBS and related syndromes (chronic pain syndrome, fibromyalgia and chronic pelvic pain syndrome) can affect the quality of life and cause decline in school performance in children. Even though the primary aim of this study is not to evaluate quality of life, successful treatment of pain and abdominal discomfort symptoms with trimebutine maleate will support the healthy psychosocial development and quality of life in children.

show abstract

“…In the early postoperative period, endogenous NO is a major inhibitory component that seems to constitute the common final pathway of mediators and the neural pathways inhibiting gastrointestinal motility in rats. Trimebutine, a weak non selective opioid agonist unable to cross blood-brain barrier, has long been used in the treatment of functional bowel disease (Delvaux & Wingate, 1997). Peripheral κ-opioid agonists are not associated with GI dysmotility but they do have antinociceptive effects in the GI tract.…”

Section: Disscusionmentioning

confidence: 99%